One day closer to meeting Jesus :-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
imo to my previous text
Definitely not feeling all the warm fuzzies I felt a while back. Short term (2-4mo) does not look real promising, especially with no current funding lined up...ugh
Not sure we see that pps after tax loss selling. A bunch of folks under water here. Significant events are a ways out imo to 2022 and beyond
Jeremiah 29:11
For I know the plans I have for you, says the Lord, plans for welfare and not for evil, to give you a future and a hope.
Proverbs 1:8-9
Hear, my son, your father’s instruction, and reject not your mother’s teaching; for they are a fair garland for your head, and pendants for your neck.
Psalm 62:1
To the choirmaster: according to Jeduthun. A Psalm of David.
For God alone my soul waits in silence; from him comes my salvation.
TSOI News...10/11
NEWS 10/11/21 Therapeutic Solutions International Announces Initiation of JadiCell™ Manufacturing Program to Address Upcoming FDA Phase III Trial and Emergency Use Requests
Company Files Over One Thousand Claim Manufacturing Patent and Begins Pilot Production Runs
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-initiation-of-jadicell-manufacturing-program-to-address-upcoming-fda-phase-iii-trial-and-emergency-use-requests-301396937.html
ELK CITY, Idaho, Oct. 11, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today initiation of pilot batch production of JadiCells, its umbilical cord stem cell product cleared by the FDA to enter Phase III clinical trials for COVID-19.
Company scientists have successfully reproduced manufacturing protocols described in the issued US patent # 9,803,176 B2 which is exclusively licensed for pulmonary indications, chronic traumatic encephalopathy, and traumatic brain injury. Additionally, the Company has filed an extensive patent covering novel manufacturing procedures as well as "second generation" JadiCells.
"Seeing myself as a man of science, the fact that we have successfully reproduced in our own hands the isolation and scalable generation of JadiCells, according to the protocols used in previously published clinical trials, is a fundamental milestone" said Dr. Thomas Ichim, Board Member of the Company, and co-inventor of the manufacturing patent. "As we prepare to launch the Phase III clinical trial in COVID-19 we need to ensure that manufacturing procedures utilized are practical and economical. The data generated by the team, as well as the various advancements that we have filed intellectual property on significantly reduce the cost of production."
Cellular therapies are characterized by extremely high costs and need for complicated procedures during manufacturing, transportation, and administration. Therapeutic Solutions International aims to increase the practicality and reduce barriers to entry for physicians wishing to utilize this "living medicine" in their patients.
"Due to the enormous interest in utilizing JadiCells domestically under the Right to Try Law and domestically and internationally under Emergency Use Authorization, as well as our upcoming Phase III clinical trial, we have decided as a Company to initiate internal manufacturing" said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "I am thankful for the efforts of our team in developing and validating the numerous Standard Operating Procedures associated with cell manufacturing, as well their innovations which have led to, in my opinion, an unparalleled patent being filed."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Related Links
https://therapeuticsolutionsint.com
Isaiah 43:11-12
I, I am the Lord, and besides me there is no savior. I declared and saved and proclaimed, when there was no strange god among you; and you are my witnesses,” says the Lord.
Psalm 63:1
A Psalm of David, when he was in the Wilderness of Judah.
O God, thou art my God, I seek thee, my soul thirsts for thee; my flesh faints for thee, as in a dry and weary land where no water is.
Isaiah 26:4
Trust in the Lord for ever, for the Lord God is an everlasting rock.
Isaiah 55:6
“Seek the Lord while he may be found, call upon him while he is near;
Proverbs 27:1
Do not boast about tomorrow, for you do not know what a day may bring forth.
TSOI News...10/04
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies
ELK CITY, Idaho, Oct. 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today laboratory data demonstrating that exosomes produced by JadiCells™, the Company's Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps.
Neutrophil extracellular traps are a network of extracellular DNA, histones, and enzymes that cause inflammation. In healthy individuals, neutrophil extracellular traps are very useful in fighting bacterial infections. Unfortunately, in conditions such as COVID-19, atherosclerosis, cancer, and various autoimmune diseases, neutrophil extracellular traps are considered to play a major role in disease initiation and progression1.
In a series of experiments JadiCells and other mesenchymal stem cells were stimulated using agents that replicate biological "danger signals". It was observed that the cells produced exosomes, which when added to neutrophils, would inhibit the production of neutrophil extracellular traps. The experimental data is part of a patent application that was submitted today.
"Due to the small size of exosomes, their ease of production, and the fact that they are made from stem cells that are recognized by the FDA, we anticipate rapid translation of this new approach into potential treatments for a variety of inflammation associated conditions," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Preliminary data suggests that the exosomes themselves possess potent lung protective activity in animal models of lung injury simple to COVID-19. This gets us excited because it opens the possibility for increasing our product pipeline."
"The lifeblood of our Company is the germination of thought into working applications. The findings described today are particularly exciting to us because they point to a potentially new mechanism by which stem cells, and the exosomes they produce, affect inflammation," said Timothy Dixon, President and CEO of the Company and co-inventor. "By targeting broadly acting molecular targets we have the opportunity to develop First in Class approaches towards diseases, which have significant possibility of sale or partnership with Big Pharma."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
TSOI...form 4 10/01
nice form 4 CEO bought 40K worth Id say that bodes very well for our future
https://www.otcmarkets.com/filing/html?id=15259856&guid=R4swkWjD9Gs3E3h
Matthew 5:11-12
“Blessed are you when men revile you and persecute you and utter all kinds of evil against you falsely on my account. Rejoice and be glad, for your reward is great in heaven, for so men persecuted the prophets who were before you.
Philippians 1:9-10
And it is my prayer that your love may abound more and more, with knowledge and all discernment, so that you may approve what is excellent, and may be pure and blameless for the day of Christ,
John 3:20-21
For every one who does evil hates the light, and does not come to the light, lest his deeds should be exposed. But he who does what is true comes to the light, that it may be clearly seen that his deeds have been wrought in God.
1 Corinthians 2:14
The unspiritual man does not receive the gifts of the Spirit of God, for they are folly to him, and he is not able to understand them because they are spiritually discerned.
Matthew 6:33
But seek first his kingdom and his righteousness, and all these things shall be yours as well.
TSOI News...9/27
NEWS 9/27/21 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing
Company with Stem Cell in FDA Cleared Phase III COVID-19 Clinical Trial Comments on Scientific Support for Nutraceutical Already on the Market
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-discusses-claims-of-possible-covid-19-suppressive-activity-of-quadramune-ingredients-by-independent-universities-made-after-patent-filing-301385491.html
ELK CITY, Idaho, Sept. 27, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI).
On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune™, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.
On November 24th, 2020, TSOI announced results of a clinical trial demonstrating in healthy volunteers that QuadraMune™ increases natural killer cell activity2. Natural killer cells are believed to be part of the body's "innate" immune response to viral infections such as SARS-CoV-2, the causative agent of COVID-19.
On December 1st, 2020, TSOI reported the results of another clinical trial in which QuadraMune™ was shown to increase interleukin 2, a protein associated with T cell responses3. T cells are considered the "adaptive" arm of the immune system and are needed for creation of immunological memory to prevent re-infections.
Following TSOI's initial research, there have been multiple studies published in peer-reviewed journals by independent academic institutions supporting the individual ingredients in QuadraMune™, which are listed below by ingredients.
To our knowledge, QuadraMune™ is the only nutraceutical on the market with this level of independent scientific support for its potential use in COVID-19.
QuadraMune™ Ingredient #1: Pterostilbene:
- November 11th, 2020. Researchers at the University of Ha'il, Saudi Arabia, used computer modeling to screen 200,000 natural compounds for the ability to block interaction between SARS-CoV2 Spike Protein and ACE2 receptor. They found pterostilbene to be the top 2 blocker of this interaction, which is critical for the virus to infect cells4.
- July 10th, 2021. Researchers at the University of Groningen in the Netherlands reported "resveratrol and its metabolically more stable structural analog, pterostilbene, exhibit potent antiviral properties against SARS-CoV-2 in vitro5."
QuadraMune Ingredient #2: Thymoquinone:
- July 12th, 2020. Researchers at University of Casablanca, Morocco reported thymoquinone may have inhibitory activities against SARS CoV2 protease. Activity of the protease is needed for the virus to replicate6.
- November 3rd, 2020. Scientists at University of Dalian, China, demonstrated thymoquinone prevents kidney damage in a mouse model of systemic inflammation resembling COVID-197.
- March 3rd, 2021. A paper from the Graduate School of Pharmaceutical Sciences in South Korea entitled "Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure" described why thymoquinone, the active ingredient in Nigella Sativa seeds possesses numerous therapeutic properties making it an ideal adjuvant or monotherapy for COVID-198.
- September 6th, 2021. A randomized clinical trial with 173 COVID-19 patients revealed that 62% of patients who received nigella sativa oil (source of thymoquinone) recovered, whereas only 36% recovered who received placebo9. The study was a collaboration between multiple hospitals in Saudi Arabia.
QuadraMune Ingredient #3: Epigallocatechin-3-gallate (EGCG)
- Sept 3rd, 2020. Researchers from Yonsei University in South Korea demonstrated EGCG inhibits SARS-CoV-2 proliferation. They demonstrated mechanistically that this process worked through suppression of 3CL-proteins, which the virus uses to generate its protein components after it has infected cells10. These findings were replicated by two independent groups11,12.
- April 13th, 2021. A study led by a group of scientists from the Paul-Ehrlich-Institute at the Department of Virology in Germany showed that EGCG suppressed SARS-CoV-2 virus in vitro13. This was replicated by independent groups14,15.
- August 10th, 2021. Researchers at the Russian Academy of Sciences reported EGCG suppresses original and SARS-CoV-2 variant (mutant) virus replication16. This data was independently verified17.
QuadraMune Ingredient #4: Sulforaphane
- March 25th, 2021. Scientists from John Hopkins published that sulforaphane reduces proliferation of SARS-CoV-2 in the laboratory, as well as in mice18.
- July 8th, 2021. Researchers at University of Ferrara, Italy published that sulforaphane decreases toxic cytokines produced by lung cells in response to parts of the SARS-CoV-1 virus19.
Timothy Dixon, President and CEO of Therapeutic Solutions International, stated, "the fact that there was no mention of COVID-19 altering activity of any of the QuadraMune™ ingredients prior to our patent filing, and that now these ingredients are being actively investigated as possible therapies speaks volumes about the wisdom of our scientific team and our advisors who have worked tirelessly at developing QuadraMune™, as well as advancing its science. With the rise of the new variants, as well as realization of the problem of "long hauler" pathologies, we believe that there is an increasing need for natural approaches towards this pandemic."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
1 Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™ | BioSpace
2 QuadraMune™ Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial (prnewswire.com)
3 Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data (prnewswire.com)
4 Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates | SpringerLink
5 Viruses | Free Full-Text | Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air–Liquid Interface Cultured Human Primary Bronchial Epithelial Cells (mdpi.com)
6 In Silico Investigation of the SARS CoV2 Protease with Thymoquinone, the Major Constituent of Nigella Sativa | Bentham Science (eurekaselect.com)
7 Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice (hindawi.com)
8 Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID–19 prevention and cure - Islam - 2021 - Phytotherapy Research - Wiley Online Library
9 Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial – ScienceDirect
10 Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro (hindawi.com)
11 The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease – ScienceDirect
12 Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2 – ScienceDirect
13 The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection | Microbiology Society (microbiologyresearch.org)
14 Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain | Journal of Agricultural and Food Chemistry (acs.org)
15 Molecules | Free Full-Text | Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19 (mdpi.com)
16 EGCG as an anti-SARS-CoV-2 agent: Preventive versus therapeutic potential against original and mutant virus – ScienceDirect
17 Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor | Cell & Bioscience | Full Text (biomedcentral.com)
18 Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses | bioRxiv
19 Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein - ScienceDirect
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Related Links
therapeuticsolutionsint.com
Hebrews 10:35-36
Therefore do not throw away your confidence, which has a great reward. For you have need of endurance, so that you may do the will of God and receive what is promised.
Romans 5:3-4
More than that, we rejoice in our sufferings, knowing that suffering produces endurance, and endurance produces character, and character produces hope,
Romans 15:7
Welcome one another, therefore, as Christ has welcomed you, for the glory of God.
TSOI News...9/22/21
NEWS 9/22/21 Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model
Exogenous T Regulatory Cells Demonstrated to Augment Activity of JadiCell Universal Donor Stem Cells Cleared for FDA Phase III Trials in COVID-19
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-discovers-and-files-patent-on-novel-cellular-therapy-combination-for-augmentation-of-lung-repair-in-covid-19-model-301382566.html
ELK CITY, Idaho, Sept. 22, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a patent demonstrating synergistic suppression of lung injury and acceleration of lung regeneration by combining T regulatory cells and JadiCells.
In a series of experiments synergistic suppression of lung damage was observed in the endotoxin and Poly (IC) models when umbilical cord blood T regulatory cells were co-administered with JadiCells. Furthermore, blockade of GITR, a member of the TNF receptor superfamily, resulted in suppression of synergy, suggesting a molecular mechanism of this interaction.
"I believe science does not stop and cannot be stopped. Therefore, as a Company, we are always seeking new ways of enhancing efficacy of our therapies, as well as elucidating molecular mechanisms causing our therapies to work," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The current discovery provides for novel means of suppressing lung damage, as well as preventing long term-scarring which is a major issue in certain COVID-19 patients."
Lung damage after COVID-19 is believed to be caused by deposition of scar tissue in the functional areas of the lung, which has been quantified to cause dysfunctional breathing for as long as 9 months after infection1. JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
"As the COVID-19 pandemic continues its merciless progression, it is becoming more and more important to create second and third generation approaches," said Famela Ramos, Vice President of Business Development. "Today's findings open the door not only towards new approaches but also towards alternative means of manipulating JadiCells using the newly discovered importance of the GITR pathway."
"We are currently continuing experiments to try to identify other molecular switches which can be used to not only enhance JadiCell activity but also activity of numerous other types of stem cells," said Timothy Dixon, President and CEO of the Company and co-inventor of patent. "As we are preparing to initiate the recently cleared FDA Phase III trial on COVID-19 patients, we wish to know as many details as possible about our cells in order to capture as much value as possible from the planned clinical trial."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
1 Study confirms longer-term lung damage after COVID-19 (newswise.com)
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Related Links
https://therapeuticsolutionsint.com
2 Corinthians 13:14
The grace of the Lord Jesus Christ and the love of God and the fellowship of the Holy Spirit be with you all.
Joel 2:23
“Be glad, O sons of Zion, and rejoice in the Lord, your God; for he has given the early rain for your vindication, he has poured down for you abundant rain, the early and the latter rain, as before.
Ephesians 5:1
Therefore be imitators of God, as beloved children.
Doog...so with all that's going on do you think we have a chance of breaking the 52wk high of .1729 iyo?
sure hope you are right on the KABOOM, Doog!
James 3:1
3Who is wise and understanding among you? By his good life let him show his works in the meekness of wisdom.
1 John 4:16
So we know and believe the love God has for us. God is love, and he who abides in love abides in God, and God abides in him.
TSOI News...9/13
NEWS 9/13/21 Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell™ Adult Stem Cells Under Right to Try Law
FDA Phase III COVID-19 Clinical Trial Company Offers Pro Bono Cell Therapy for Veterans at Risk
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-successfully-treats-veteran-navy-seal-suffering-from-chronic-traumatic-encephalopathy-with-jadicell-adult-stem-cells-under-right-to-try-law-301375088.html
ELK CITY, Idaho, Sept. 13, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today successful treatment of a United States Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE). The patient received 2 injections of the JadiCell adult stem cells, no treatment associated adverse events were noted.
The cells were provided under a newly initiated program under which Therapeutic Solutions International provides access to its technologies Pro Bono, to members of the Armed Forces who have defended the United States.
"We are 100% committed to performing proper clinical trials, as seen by the recent Phase III clearance to utilize these cells in patients with COVID-19 ARDS. We are also working with the FDA to launch our Phase I/II trial in CTE," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "With a suicide rate of 20 veterans per day, it is imperative that we vigorously explore novel therapeutic strategies in patients for which other approaches have failed or don't exist. Given the excellent safety profile of these cells, and promising preclinical data, in our opinion it would be criminal not to provide access to these cells under very specific circumstances."
CTE is caused by repeated injuries to the brain causing chronic inflammation, deterioration of neuronal communication, and death of brain cells. These culminate in various symptomologies including depression, violence, and suicidality.
"My father was a combat veteran Marine of WWII and Korea; I fully understand the extreme sacrifices made by members of our Armed Forces in the defense of our Freedom, our Nation, and our National Security," said Timothy Dixon, President and CEO of the Company. "We are a Company that is proud of being in a position to give something back to the bravest segment of our society."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Related Links
therapeuticsolutionsint.com
Philippians 2:1-2
So if there is any encouragement in Christ, any incentive of love, any participation in the Spirit, any affection and sympathy, complete my joy by being of the same mind, having the same love, being in full accord and of one mind.
1 Peter 3:8
Finally, all of you, have unity of spirit, sympathy, love of the brethren, a tender heart and a humble mind.
News today was very encouraging today and shows a sense of urgency imo
TSOI News....9/10
NEWS 9/10/21 Therapeutic Solutions International Engages Venvalo Group to Oversee JadiCell COVID-19 Phase III Clinical Trial and Emergency Use Authorization (EUA) Process
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-engages-venvalo-group-to-oversee-jadicell-covid-19-phase-iii-clinical-trial-and-emergency-use-authorization-eua-process-301373258.html
ELK CITY, Idaho, Sept. 10, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the engagement of Venvalo Group to assist the Company on regulatory, strategic, and implementation aspects of the recently FDA-cleared Phase III clinical trial assessing ability of JadiCells to treat patients with advanced COVID-19.
"I have known Dr. Boris Reznik for many years and have seen first-hand his ability to rapidly grow companies and perform clinical trials in a variety of disease indications including COVID-19," said Dr. Camillo Ricordi, Principal Investigator of the initial clinical trial, whose promising results resulted in the current FDA approval to proceed with a multi-site, Phase III trial. "Being in the middle of the biggest biological threat that our generation has witnessed, I believe it is imperative to work with top quality groups to rapidly complete this trial and bring this new treatment to patients as quickly as possible."
In 2020 Dr. Ricordi led the international team that successfully completed the first FDA approved controlled trial to treat the most severe cases of COVID-19 with stem cell infusions1. The unprecedented results allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, and 91% survival in subjects of all ages, compared to 42% survival in the control group.
"The work of Dr. Ricordi has significantly impacted the field of medicine in areas of Type 1 Diabetes, regenerative medicine, and transplant immunology," stated Dr. Boris Reznik, Chairman of Venvalo Group. "We are proud to work with this Medical Visionary and to perform the most rapid and effective clinical translation of this novel and life-saving technology as soon as we can."
"By leveraging the knowledge gained from the hundreds of clinical trials performed by Dr. Reznik at bioRASI, as well as the unsurpassed innovative abilities of Dr. Ricordi, we are excited to rapidly move forward with the current clinical trial, as well as the Emergency Use Application, which is currently under development," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/
1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial
ir@tsoimail.com
SOURCE Therapeutic Solutions International
Isaiah 46:4
even to your old age I am He, and to gray hairs I will carry you. I have made, and I will bear; I will carry and will save.
Titus 2:2
Bid the older men be temperate, serious, sensible, sound in faith, in love, and in steadfastness.
Psalm 143:10
Teach me to do thy will, for thou art my God! Let thy good spirit lead me on a level path!
Colossians 1:28
Him we proclaim, warning every man and teaching every man in all wisdom, that we may present every man mature in Christ.